KALAMAZOO, MICH. September 18, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company will host a webcast and conference call today, September 18, 2017, to discuss the recent leadership transition, current priorities and its commercial strategy.
Investor Conference Call Details
Date: Monday, September 18, 2017 Time: 10 AM EST
Materials for the Investor Conference Call will be made available at 7:00 AM EST on September 18, 2017
The slides can be accessed HERE.
Telephone:
North American callers, dial 800 681 1924. International callers, dial +1 303 223 4393
There is no access code required. Simply call into the assigned phone number.
An archive of the slides will be available at www.medizoneint.com A replay of the conference call will be available from September 18, 2017 at 12:00 PM EST through September 25, 2017 at 12:00 PM EST by calling 800 633 8284. The access code for the replay is 21859116. The slides, conference call, and replay are open to all interested parties.
About Medizone International, Inc.
Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure® system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure® system for use in Canada, and several other global markets.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.
For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: j.pentony@medizoneint.com
For more information, visit:
www.medizoneint.com
Email: operations@medizoneint.com
